BTX-A51

BTX-A51 is an inhibitor of CK2 used in studies of Apoptosis. In practice, this places the compound in experiments that measure caspase-associated cell-death signaling and survival decisions in apoptosis, cancer, and cell cycle models.

By inhibiting CK2, BTX-A51 can be used to examine caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and cell cycle models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CK2
• Pathway perturbation studies connected to Apoptosis
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, BTX-A51 is appropriate when a defined chemical perturbant is needed to connect CK2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and cell cycle models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.